666 results on '"Yong, Wei-Peng"'
Search Results
152. Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
153. 675 INTRA-PERITONEAL PACLITAXEL IN COMBINATION WITH SYSTEMIC XELOX FOR GASTRIC CANCER WITH PERITONEAL METASTASES: RESULTS FROM A SINGAPOREAN PHASE II TRIAL
154. 590 AN ORGANOID-IMMUNE CELL CO-CULTURE PREDICTIVE MODEL TO TARGET HER2/PD-L1 POSITIVE GASTRIC CANCERS
155. An Organoid Approach to Target Her2/PD‐L1 Positive Gastric Cancers
156. Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.
157. Safety and tolerability of oxaliplatin based pressurized intraperitoneal aerosol chemotherapy (PIPAC) for patients with peritoneal carcinomatosis: A phase I dose-finding study in Asian patients.
158. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial
159. Targeted therapeutics-oriented tumor classification: a paradigm shift
160. The role of pharmacogenetics in cancer therapeutics
161. An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models
162. A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).
163. Prospective validation of a serum miRNA panel for early detection of gastric cancer.
164. A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).
165. AB046. P-14. TREETOPP: a phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs)
166. AB063. P-34. A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment naïve advanced or metastatic biliary tract cancer (BTC)
167. AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
168. A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).
169. Single-cell analysis of immune-microenvironment and immune-tumor interaction in human gastric cancers.
170. Predictors of survival outcome following radical gastrectomy for gastric cancer
171. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
172. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
173. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
174. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
175. A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs
176. The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer
177. Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis
178. Validation of a LC-MS/MS Method for Quantitative Analysis of MELK Inhibitor OTS167 in Mouse Serum: Application to a Pharmacokinetic Study
179. A Sensitive Liquid Chromatography-tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study
180. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
181. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients
182. TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
183. Clinical outcome and prognostic factors for Asian patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS).
184. Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.
185. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
186. Resisting resistance to cancer immunotherapy
187. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
188. Abstract B035: Evaluation of a novel monoclonal antibody targeting ASC amino acid transporter 2 using patient-derived xenograft mouse models of gastric cancer
189. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
190. Tweak to Treat: Reprograming Bacteria for Cancer Treatment
191. The topography of DNA methylation in the non-neoplastic colonic mucosa surrounding colorectal cancers
192. Iqgap3-Ras axis drives stem cell proliferation in the stomach corpus during homoeostasis and repair
193. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population
194. Numerical Simulation on the Influence of Mining-Induced Fractures Field on Gas Drainage and its Application
195. Theory and test research on permeability of coal and rock body influenced by mining
196. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer
197. Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study
198. Chemotherapy for advanced gastric cancer
199. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
200. Whole exome sequencing (WES) of multiple spatially distinct biopsies from single metastatic lesions to evaluate tumour heterogeneity and identify actionable truncal mutations (ATMs) in patients (pts) with advanced solid malignancies using a radiologically-guided single-pass percutaneous technique.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.